Free Trial
NASDAQ:TNXP

Tonix Pharmaceuticals Q1 2025 Earnings Report

Tonix Pharmaceuticals logo
$24.00 -0.72 (-2.91%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$24.00 +0.00 (+0.00%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tonix Pharmaceuticals EPS Results

Actual EPS
-$3.86
Consensus EPS
-$3.10
Beat/Miss
Missed by -$0.76
One Year Ago EPS
N/A

Tonix Pharmaceuticals Revenue Results

Actual Revenue
$2.00 million
Expected Revenue
$2.60 million
Beat/Miss
Missed by -$600.00 thousand
YoY Revenue Growth
N/A

Tonix Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Tonix Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tonix Pharmaceuticals Earnings Headlines

Tonix Pharma Appoints New Head of Market Access
China’s message to Trump
Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in his urgent broadcast, he names three investments he believes could soar as America’s financial system nears a breaking point.tc pixel
See More Tonix Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tonix Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tonix Pharmaceuticals and other key companies, straight to your email.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ:TNXP) is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD. The company is conducting late-stage clinical trials to assess safety and efficacy in people who experience chronic pain and disrupted sleep due to these conditions. In addition to its CNS portfolio, Tonix is advancing live-virus vaccine candidates against orthopoxviruses, including those that could be used for smallpox or monkeypox, and is exploring development of vaccines against other biothreat agents.

Headquartered in New York, Tonix Pharmaceuticals leverages in-house research and collaborations with academic institutions and government agencies to advance its pipeline. The company was co-founded and is led by Seth H. Lederman, M.D., who serves as President and Chief Executive Officer. Under Dr. Lederman’s direction, Tonix continues to progress multiple programs through clinical development while maintaining a focus on unmet medical needs in both therapeutic and vaccine arenas.

View Tonix Pharmaceuticals Profile

More Earnings Resources from MarketBeat